Viatris Keeping Powder Dry On Symbicort With Key Ruling Imminent
US-Based Firm Facing Second Suit With November Trial Scheduled
Executive Summary
In the coming days, Viatris expects to hear back from a court in West Virginia over its legal tussle with AstraZeneca on Symbicort IP. The US-based player has intimated that it may launch the product dependent on the court’s verdict.
You may also be interested in...
Momenta Sues Viatris Over Copaxone Generic – Five Years After Launch
One Copaxone (glatiramer acetate) ANDA sponsor is suing another for alleged patent infringement, with Momenta filing a lawsuit against Viatris and its partners in a US district court.
AZ: US Federal Circuit 'Flagrantly Violated Precedent' On Symbicort
The US Court of Appeals for the Federal Circuit has “abandoned the basic principles of significant figures that have long been recognized by this court,” AstraZeneca argues, as part of its petition to have reheard a recent verdict favoring Mylan on the originator’s Symbicort IP.
US Supreme Court Reignites Claims Government Overcharged Millions For Generics
In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.